University of Vienna
His primary areas of investigation include Internal medicine, Rheumatoid arthritis, Arthritis, Immunology and Rheumatology. Josef S. Smolen has researched Internal medicine in several fields, including Endocrinology, Surgery and Physical therapy. His Rheumatoid arthritis research incorporates themes from Gastroenterology, Placebo, Infliximab and Chemotherapy.
The concepts of his Arthritis study are interwoven with issues in Inflammation, Osteoclast, Cartilage and Pathology. His studies deal with areas such as Tumor necrosis factor alpha and Inflammatory arthritis as well as Osteoclast. Josef S. Smolen interconnects Disease activity, Systemic lupus erythematosus and Rheumatoid factor in the investigation of issues within Rheumatology.
His scientific interests lie mostly in Internal medicine, Rheumatoid arthritis, Immunology, Arthritis and Rheumatology. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Endocrinology and Surgery. His Rheumatoid arthritis study integrates concerns from other disciplines, such as Tumor necrosis factor alpha, Infliximab, Disease, Clinical trial and Physical therapy.
His biological study spans a wide range of topics, including Rheumatism and Severity of illness. His Arthritis research is multidisciplinary, relying on both Inflammation, Proinflammatory cytokine, Osteoclast and Pathology. His Autoantibody research includes themes of Epitope, Lupus erythematosus, Autoimmune disease and Autoimmunity.
Josef S. Smolen focuses on Internal medicine, Rheumatoid arthritis, Arthritis, Physical therapy and Disease activity. In his study, which falls under the umbrella issue of Internal medicine, Placebo and Golimumab is strongly linked to Gastroenterology. Rheumatoid arthritis is a subfield of Immunology that Josef S. Smolen investigates.
Josef S. Smolen has included themes like Psoriasis, Osteoclast and Pathology in his Arthritis study. The Physical therapy study combines topics in areas such as Observational study, Quality of life, Intensive care medicine, Rheumatism and Disease. As part of one scientific family, Josef S. Smolen deals mainly with the area of Disease activity, narrowing it down to issues related to the Phases of clinical research, and often Secukinumab and Minimal disease.
His main research concerns Rheumatoid arthritis, Physical therapy, Internal medicine, Rheumatology and Clinical trial. His Rheumatoid arthritis study combines topics from a wide range of disciplines, such as Disease activity, Severity of illness, Epidemiology and Arthritis. The various areas that Josef S. Smolen examines in his Arthritis study include Proteoglycan and Etanercept.
His Internal medicine research integrates issues from Cross-sectional study and Surgery. His Rheumatology study frequently draws connections to other fields, such as Placebo. His work carried out in the field of Clinical trial brings together such families of science as Biosimilar, Systematic review, Immunology and Rheumatoid factor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
R Maini;E W St Clair;F Breedveld;D Furst.
The Lancet (1999)
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
M J Elliott;R N Maini;M Feldmann;J R Kalden.
The Lancet (1994)
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen.
Arthritis & Rheumatism (1998)
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.
Claudio Vitali;Stefano Bombardieri;Haralampos M. Moutsopoulos;Genesio Balestrieri.
Arthritis & Rheumatism (1993)
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
W. Zhang;M. Doherty;B. F. Leeb;L. Alekseeva.
Annals of the Rheumatic Diseases (2005)
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
J.S. Smolen;F.C. Breedveld;M.H. Schiff;J.R. Kalden.
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Bernard Combe;Robert Landewé;Cedric Lukas;Horatio D Bolosiu.
Annals of the Rheumatic Diseases (2006)
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial
Josef S Smolen;Joachim R Kalden;David L Scott;Blaz Rozman.
The Lancet (1999)
Range of antinuclear antibodies in "healthy" individuals
E. M. Tan;T. E. W. Feltkamp;J. S. Smolen;B. Butcher.
Arthritis & Rheumatism (1997)
Autoantigen microarrays for multiplex characterization of autoantibody responses
William H. Robinson;Carla DiGennaro;Wolfgang Hueber;Brian B. Haab.
Nature Medicine (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: